Silence Therapeutics (SLN) Invested Capital (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Invested Capital for 7 consecutive years, with $62.3 million as the latest value for Q4 2025.
- Quarterly Invested Capital fell 53.51% to $62.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.3 million through Dec 2025, down 53.51% year-over-year, with the annual reading at $62.3 million for FY2025, 53.51% down from the prior year.
- Invested Capital hit $62.3 million in Q4 2025 for Silence Therapeutics, down from $74.1 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $156.8 million in Q1 2024 to a low of $11.5 million in Q4 2021.
- Historically, Invested Capital has averaged $87.4 million across 5 years, with a median of $94.2 million in 2025.
- Biggest five-year swings in Invested Capital: soared 533.33% in 2024 and later plummeted 53.51% in 2025.
- Year by year, Invested Capital stood at $11.5 million in 2021, then skyrocketed by 125.26% to $25.9 million in 2022, then dropped by 18.26% to $21.2 million in 2023, then skyrocketed by 533.33% to $134.0 million in 2024, then tumbled by 53.51% to $62.3 million in 2025.
- Business Quant data shows Invested Capital for SLN at $62.3 million in Q4 2025, $74.1 million in Q3 2025, and $94.2 million in Q2 2025.